NASDAQ: NMRA

Neumora Therapeutics Inc Stock Forecast, Predictions & Price Target

The consensus among 2 Wall Street analysts covering (NASDAQ: NMRA) stock is to Strong Buy NMRA stock.

Out of 2 analysts, 1 (50%) are recommending NMRA as a Strong Buy, 1 (50%) are recommending NMRA as a Buy, 0 (0%) are recommending NMRA as a Hold, 0 (0%) are recommending NMRA as a Sell, and 0 (0%) are recommending NMRA as a Strong Sell.

If you're new to stock investing, here's how to buy Neumora Therapeutics stock.

(NASDAQ: NMRA) Neumora Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.94%.

Neumora Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast NMRA's revenue for 2026 to be $2,653,874,545, with the lowest NMRA revenue forecast at $1,845,620,949, and the highest NMRA revenue forecast at $3,462,128,141. On average, 2 Wall Street analysts forecast NMRA's revenue for 2027 to be $25,046,328,303, with the lowest NMRA revenue forecast at $17,638,740,503, and the highest NMRA revenue forecast at $32,454,074,990.

In 2028, NMRA is forecast to generate $53,762,448,881 in revenue, with the lowest revenue forecast at $38,056,875,570 and the highest revenue forecast at $69,468,181,079.

According to 2 Wall Street analysts that have issued a 1 year NMRA price target, the average NMRA price target is $26.50, with the highest NMRA stock price forecast at $31.00 and the lowest NMRA stock price forecast at $22.00.

On average, Wall Street analysts predict that Neumora Therapeutics's share price could reach $26.50 by Mar 28, 2025. The average Neumora Therapeutics stock price prediction forecasts a potential upside of 189.62% from the current NMRA share price of $9.15.

(NASDAQ: NMRA) forecast ROE is N/A, which is considered weak.